2. Academic Validation
  3. COTI-2, A Novel Thiosemicarbazone Derivative, Exhibits Antitumor Activity in HNSCC through p53-dependent and -independent Mechanisms

COTI-2, A Novel Thiosemicarbazone Derivative, Exhibits Antitumor Activity in HNSCC through p53-dependent and -independent Mechanisms

  • Clin Cancer Res. 2019 Sep 15;25(18):5650-5662. doi: 10.1158/1078-0432.CCR-19-0096.
Antje Lindemann  # 1,  Ameeta A Patel  # 1,  Natalie L Silver 2,  Lin Tang 3,  Zhiyi Liu 1,  Li Wang 4,  Noriaki Tanaka 5,  Xiayu Rao 6,  Hideaki Takahashi 1,  Nakachi K Maduka 1,  Mei Zhao 1,  Tseng-Cheng Chen 7,  WeiWei Liu 8,  Meng Gao 1,  Jing Wang 6,  Steven J Frank 4,  Walter N Hittelman 9,  Gordon B Mills 10,  Jeffrey N Myers  # 11,  Abdullah A Osman  # 11
Affiliations

Affiliations

  • 1 Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • 2 Department of Otolaryngology, Division of Head and Neck Oncologic Surgery, University of Florida College of Medicine, Gainesville, Florida.
  • 3 Department of Cellular and Molecular Medicine, The University of Arizona Health Sciences, College of Medicine, Tucson, Arizona.
  • 4 Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • 5 Department of Dentistry and Oral Surgery, Osaka Police Hospital, Osaka, Japan.
  • 6 Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • 7 Department of Otolaryngology, National Taiwan University Hospital, Taipei, Taiwan.
  • 8 Department of Oral Surgery, School of Stomatology, Jilin University, Changchun, Jilin, China.
  • 9 Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer, Houston, Texas.
  • 10 Oregon Health & Science University, Knight Cancer Institute, Portland, Oregon.
  • 11 Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas. [email protected] [email protected].
  • # Contributed equally.
PMID: 31308060 DOI: 10.1158/1078-0432.CCR-19-0096
Abstract

Purpose: TP53 mutations are highly prevalent in head and neck squamous cell carcinoma (HNSCC) and associated with increased resistance to conventional treatment primarily consisting of chemotherapy and radiation. Restoration of wild-type p53 function in TP53-mutant Cancer cells represents an attractive therapeutic approach and has been explored in recent years. In this study, the efficacy of a putative p53 reactivator called COTI-2 was evaluated in HNSCC cell lines with different TP53 status.Experimental Design: Clonogenic survival assays and an orthotopic mouse model of oral Cancer were used to examine in vitro and in vivo sensitivity of HNSCC cell lines with either wild-type, null, or mutant TP53 to COTI-2 alone, and in combination with cisplatin and/or radiation. Western blotting, cell cycle, live-cell imaging, RNA sequencing, reverse-phase protein array, chromatin immunoprecipitation, and Apoptosis analyses were performed to dissect molecular mechanisms.

Results: COTI-2 decreased clonogenic survival of HNSCC cells and potentiated response to cisplatin and/or radiation in vitro and in vivo irrespective of TP53 status. Mechanistically, COTI-2 normalized wild-type p53 target gene expression and restored DNA-binding properties to the p53-mutant protein in HNSCC. In addition, COTI-2 induced DNA damage and replication stress responses leading to Apoptosis and/or senescence. Furthermore, COTI-2 lead to activation of AMPK and inhibition of the mTOR pathways in vitro in HNSCC cells.

Conclusions: COTI-2 inhibits tumor growth in vitro and in vivo in HNSCC likely through p53-dependent and p53-independent mechanisms. Combination of COTI-2 with cisplatin or radiation may be highly relevant in treating patients with HNSCC harboring TP53 mutations.

Figures
Products